Aprea Therapeutics (NASDAQ:APRE) Trading Down 2.5% – Should You Sell?

Aprea Therapeutics, Inc. (NASDAQ:APRE) shares dropped 2.5% during trading on Tuesday . The company traded as low as $0.65 and last traded at $0.6520. 43,647 shares changed hands during mid-day trading, a decline of 33% from the average session volume of 65,580 shares. The stock had previously closed at $0.6690.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on APRE. HC Wainwright dropped their target price on shares of Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Oppenheimer started coverage on Aprea Therapeutics in a research note on Thursday, May 7th. They issued an “outperform” rating and a $5.00 price target on the stock. Wedbush reduced their price objective on Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Friday. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Aprea Therapeutics has an average rating of “Hold” and an average target price of $4.07.

Aprea Therapeutics Stock Performance

The stock has a market capitalization of $8.07 million, a P/E ratio of -0.42 and a beta of 1.50. The business has a fifty day simple moving average of $0.79 and a 200-day simple moving average of $0.80.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Aprea Therapeutics had a negative return on equity of 61.03% and a negative net margin of 4,405.59%. On average, sell-side analysts anticipate that Aprea Therapeutics, Inc. will post -0.84 earnings per share for the current year.

Hedge Funds Weigh In On Aprea Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new position in Aprea Therapeutics in the 4th quarter valued at $40,000. DRW Securities LLC bought a new stake in shares of Aprea Therapeutics during the 4th quarter worth $103,000. Finally, AIGH Capital Management LLC boosted its holdings in shares of Aprea Therapeutics by 174.1% in the 1st quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock worth $775,000 after buying an additional 645,000 shares during the last quarter. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.